
The key reasons why Lineage Cell Therapeutics Inc (LCTX) is -6.09% away from 52-week high?
Witnessing the stock’s movement on the chart, on Wednesday, Lineage Cell Therapeutics Inc (AMEX: LCTX) set off with pace as it heaved 13.68% to $1.08,
Witnessing the stock’s movement on the chart, on Wednesday, Lineage Cell Therapeutics Inc (AMEX: LCTX) set off with pace as it heaved 13.68% to $1.08,
Lineage Cell Therapeutics Inc (AMEX: LCTX) started the day on Thursday, with a price decrease of -2.94% at $0.99, before settling in for the price
On Monday, Lineage Cell Therapeutics Inc (AMEX: LCTX) opened higher 3.88% from the last session, before settling in for the closing price of $1.03. Price
Lineage Cell Therapeutics Inc (AMEX: LCTX) flaunted slowness of -3.77% at $1.02, as the Stock market unbolted on Thursday, before settling in for the price
Lineage Cell Therapeutics Inc (AMEX: LCTX) kicked off on Monday, down -5.90% from the previous trading day, before settling in for the closing price of
Lineage Cell Therapeutics Inc (AMEX: LCTX) on Monday, plunged -3.02% from the previous trading day, before settling in for the closing price of $0.96. Within
Lineage Cell Therapeutics Inc (AMEX: LCTX) on Tuesday, soared 12.57% from the previous trading day, before settling in for the closing price of $0.96. Within
On Monday, Lineage Cell Therapeutics Inc (AMEX: LCTX) was 6.70% up from the session before settling in for the closing price of $0.81. A 52-week
On Monday, Lineage Cell Therapeutics Inc (AMEX: LCTX) opened higher 6.46% from the last session, before settling in for the closing price of $0.68. Price
Lineage Cell Therapeutics Inc (AMEX: LCTX) started the day on Thursday, with a price increase of 5.17% at $0.69, before settling in for the price
Newsdaemon.com is a Business and Stock news website that covers extensive information on Stock markets and Equities. One of the key emphases of this portal is to widen readers’ knowledge of public and private capital sharing, both in updates and broad analysis.
Copyright © 2024 News Daemon, All rights reserved.